What Is EGRIFTA®?
EGRIFTA® is an injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy. It is thought to work with your own body to produce natural growth hormone to reduce your excess belly fat.
- The impact and safety of EGRIFTA® on cardiovascular health has not been studied.
- EGRIFTA® is not indicated for weight loss management.
- It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.
- It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.
Results With EGRIFTA®
In two separate clinical trials, at six months, EGRIFTA® reduced HIV-related excess belly fat by an average of 18% in the first trial, and by an average of 14% in the second. This reduction in VAT showed an approximately 1-inch reduction in waist size. On average, patients on EGRIFTA® did not lose weight.
Like HIV, HIV-related excess belly fat is a chronic condition. So, people who used EGRIFTA® continuously for 1 year maintained their results over this time period. People who stopped using EGRIFTA® after 6 months had VAT come back.
Some patients with HIV-related excess belly fat can feel distressed about the appearance of their belly. In clinical trials of EGRIFTA®, a greater percentage of people who took EGRIFTA® reported an improvement in belly appearance distress than people who did not take EGRIFTA®.
Individual results may vary.
EGRIFTA® may cause serious side effects including:
Do not use EGRIFTA® if you:
- have pituitary gland tumor, pituitary gland surgery or other problems related to your pituitary gland
- have or had a history of active cancer (either newly diagnosed or recurrent)
- are allergic to tesamorelin or any of the ingredients in EGRIFTA® including mannitol or sterile water
- are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA® and talk with your healthcare provider.
Before using EGRIFTA®, tell your healthcare provider if you:
- have or have had cancer
- have diabetes
- are breastfeeding or plan to breastfeed. It is not known if EGRIFTA® passes into your breast milk. The Centers for Disease Control and Prevention (CDC) recommends that HIV-infected mothers not breastfeed to avoid the risk of passing HIV infection to your baby. Talk with your healthcare provider about the best way to feed your baby if you are taking EGRIFTA®
- have kidney or liver problems
- have any other medical condition.
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. EGRIFTA® may affect the way other medicines work, and other medicines may affect how EGRIFTA® works.
How should I use EGRIFTA®?
- Read the detailed "Instructions for Use" that comes with EGRIFTA® before you start using EGRIFTA®. Your healthcare provider will show you how to inject EGRIFTA®.
- Use EGRIFTA® exactly as prescribed by your healthcare provider.
- Inject EGRIFTA® under the skin (subcutaneously) of your stomach area (abdomen).
- Change (rotate) the injection site on your stomach area (abdomen) with each dose. Do not inject EGRIFTA® into scar tissue, bruises or your navel.
- Do not share needles or syringes with other people. Sharing of needles can result in the transmission of infectious diseases, such as HIV.